Edwards Lifesciences Corporation
EW
$85.28
-$1.90-2.18%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.07B | 5.88B | 5.69B | 5.52B | 5.44B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.07B | 5.88B | 5.69B | 5.52B | 5.44B |
| Cost of Revenue | 1.33B | 1.28B | 1.20B | 1.13B | 1.12B |
| Gross Profit | 4.73B | 4.60B | 4.48B | 4.39B | 4.32B |
| SG&A Expenses | 2.08B | 1.97B | 1.88B | 1.83B | 1.79B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -67.20M | -75.60M | -40.70M | -19.40M | -300.00K |
| Total Operating Expenses | 4.43B | 4.26B | 4.10B | 3.99B | 3.96B |
| Operating Income | 1.64B | 1.62B | 1.59B | 1.53B | 1.48B |
| Income Before Tax | 1.27B | 1.57B | 1.63B | 1.61B | 1.55B |
| Income Tax Expenses | 216.90M | 235.80M | 220.40M | 176.10M | 152.10M |
| Earnings from Continuing Operations | 1.06K | 1.34K | 1.41K | 1.43K | 1.40K |
| Earnings from Discontinued Operations | 13.40M | 25.70M | 2.74B | 2.74B | 2.77B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.10M | 5.40M | 6.00M | 5.60M | 4.90M |
| Net Income | 1.07B | 1.37B | 4.15B | 4.18B | 4.17B |
| EBIT | 1.64B | 1.62B | 1.59B | 1.53B | 1.48B |
| EBITDA | 1.79B | 1.78B | 1.73B | 1.67B | 1.62B |
| EPS Basic | 1.83 | 2.33 | 6.97 | 7.01 | 6.99 |
| Normalized Basic EPS | 1.87 | 1.77 | 1.76 | 1.74 | 1.68 |
| EPS Diluted | 1.82 | 2.32 | 6.97 | 7.01 | 6.99 |
| Normalized Diluted EPS | 1.87 | 1.76 | 1.76 | 1.74 | 1.67 |
| Average Basic Shares Outstanding | 2.34B | 2.35B | 2.36B | 2.38B | 2.39B |
| Average Diluted Shares Outstanding | 2.34B | 2.35B | 2.36B | 2.38B | 2.40B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |